These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19847468)

  • 21. [Associations of serum neuromarkers with clinical features of Parkinson's disease].
    Nikitina MA; Koroleva ES; Brazovskaya NG; Boyko AS; Levchuk LA; Ivanova SA; Alifirova VM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):145-152. PubMed ID: 38676689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.
    Levivier M; Przedborski S; Bencsics C; Kang UJ
    J Neurosci; 1995 Dec; 15(12):7810-20. PubMed ID: 8613721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects and Mechanisms of Exercise on Brain-Derived Neurotrophic Factor (BDNF) Levels and Clinical Outcomes in People with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kaagman DGM; van Wegen EEH; Cignetti N; Rothermel E; Vanbellingen T; Hirsch MA
    Brain Sci; 2024 Feb; 14(3):. PubMed ID: 38539583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moderate-intensity interval training increases serum brain-derived neurotrophic factor level and decreases inflammation in Parkinson's disease patients.
    Zoladz JA; Majerczak J; Zeligowska E; Mencel J; Jaskolski A; Jaskolska A; Marusiak J
    J Physiol Pharmacol; 2014 Jun; 65(3):441-8. PubMed ID: 24930517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BDNF as a Promising Therapeutic Agent in Parkinson's Disease.
    Palasz E; Wysocka A; Gasiorowska A; Chalimoniuk M; Niewiadomski W; Niewiadomska G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32050617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BDNF and Netrin-1 repression by C/EBPβ in the gut triggers Parkinson's disease pathologies, associated with constipation and motor dysfunctions.
    Ahn EH; Kang SS; Liu X; Cao X; Choi SY; Musazzi L; Mehlen P; Ye K
    Prog Neurobiol; 2021 Mar; 198():101905. PubMed ID: 32911010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine, BDNF and motor function postbilateral anodal transcranial direct current stimulation in Parkinson's disease.
    Hadoush H; Banihani SA; Khalil H; Al-Qaisi Y; Al-Sharman A; Al-Jarrah M
    Neurodegener Dis Manag; 2018 Jun; 8(3):171-179. PubMed ID: 29888648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.
    Mocchetti I; Bachis A; Nosheny RL; Tanda G
    Neurotox Res; 2007 Sep; 12(2):135-43. PubMed ID: 17967737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum brain-derived neurotrophic factor level in elderly women depression: a community-based study.
    Hashizume M; Hachisu M; Yoshida H; Kim M; Kim HK; Amano Y; Hasegawa C; Suzuki T; Ihara K
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():109-16. PubMed ID: 25178999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do peripheral immune and neurotrophic markers correlate with motor severity of Parkinson's disease?
    Roy A; Mondal B; Banerjee R; Choudhury S; Chatterjee K; Dey S; Kumar H
    J Neuroimmunol; 2021 May; 354():577545. PubMed ID: 33756415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plantar stimulation in parkinsonians: From biomarkers to mobility - randomized-controlled trial.
    Pagnussat AS; Kleiner AFR; Rieder CRM; Frantz A; Ehlers J; Pinto C; Dorneles G; Netto CA; Peres A; Galli M
    Restor Neurol Neurosci; 2018; 36(2):195-205. PubMed ID: 29526852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levels of cortisol and neurotrophic factor brain-derived in Parkinson's disease.
    Costa CM; Oliveira GL; Fonseca ACS; Lana RC; Polese JC; Pernambuco AP
    Neurosci Lett; 2019 Aug; 708():134359. PubMed ID: 31265872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels.
    Sanna A; Follesa P; Puligheddu M; Cannas A; Serra M; Pisu MG; Dagostino S; Solla P; Tacconi P; Marrosu F
    Neurosci Lett; 2020 Jan; 716():134653. PubMed ID: 31778767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Mak M; Deptuła-Jarosz M; Gołąb-Janowska M; Droździk M; Sławek J
    Neurosci Lett; 2014 Feb; 561():86-90. PubMed ID: 24394906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbance-Related Motor Symptoms in Patients with Parkinson's Disease.
    Chung CC; Huang PH; Chan L; Chen JH; Chien LN; Hong CT
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32932791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
    Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson's disease.
    Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Behav Brain Res; 2019 Oct; 372():112039. PubMed ID: 31202861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study.
    Huang X; Ng SY; Chia NS; Acharyya S; Setiawan F; Lu ZH; Ng E; Tay KY; Au WL; Tan EK; Tan LC
    Parkinsonism Relat Disord; 2018 Oct; 55():50-54. PubMed ID: 29779681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with Parkinson's disease in a Greek population.
    Karakasis C; Kalinderi K; Katsarou Z; Fidani L; Bostantjopoulou S
    J Clin Neurosci; 2011 Dec; 18(12):1744-5. PubMed ID: 22001244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment.
    Altmann V; Schumacher-Schuh AF; Rieck M; Callegari-Jacques SM; Rieder CR; Hutz MH
    Neurosci Lett; 2016 Feb; 615():88-91. PubMed ID: 26806863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.